P8RI
Modify Date: 2024-01-14 08:38:47
P8RI structure
|
Common Name | P8RI | ||
|---|---|---|---|---|
| CAS Number | 2147724-76-1 | Molecular Weight | 1016.24 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C51H77N13O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of P8RIP8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway[1][2]. |
| Name | P8RI |
|---|
| Description | P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases[1]. |
| In Vivo | P8RI (2.5 mg/kg; s.c.; daily from 7 to 28 after the occurrence of ADIM) prevents aneurysmal transformation by promoting the resolution of intramural hematoma and the production of collagen in dissected aortas in vivo, associated with enrichment of M2 macrophages at the site of injury[3]. Animal Model: Apo E -/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))[3] Dosage: 2.5 mg/kg Administration: Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II) Result: Aneurysmal transformation was significantly reduced. |
| References |
| Molecular Formula | C51H77N13O9 |
|---|---|
| Molecular Weight | 1016.24 |